ClinicalTrials.gg
RecruitingNCT07424222RISEUpdated Jul 28, 2026

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

A Phase 1 interventional study of Ruxolitinib in Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic — 5 open to participants now, 6 under way, none of them phase 3. ruxolitinib · Lymphohistiocytosis, Hemophagocytic.

Planned enrollment
8th of 10
16 · median 36
Started
2026
the only one that year
Phase 1
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Among the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic, this one is the 8th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 1, and was the 10th registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

5 of the 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ruxolitinib in Lymphohistiocytosis, Hemophagocytic, or all of them as a file.
02

Study summary

This is a pilot study to gather information about safety and efficacy of using ruxolitinib (RUX) to treat Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) occurring after CAR-T therapy. In addition, correlative studies will be done to 1) estimate the optimal duration of RUX therapy, 2) to identify immunological biomarkers associated with response (3) To evaluate the dynamics of CAR T expansion following RUX treatment.

Oral RUX will be administered twice daily, with dosing determined by the participant's baseline platelet count. Treatment will continue for up to 8 weeks unless significant adverse events occur or the treating physician concludes that the therapy is no longer providing clinical benefit.

The study expects to accrue 16 evaluable patients diagnosed with IEC-HS over 2 years.

03

Conditions studied

  • Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Keywords

  • CAR T
  • IEC-HS
  • ruxolitinib
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of age 18 or older
  • Diagnosis of for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) per ASTCT consensus criteria
  • Patients must have an elevated ferritin (>2 × ) at time of infusion and/or have a ferritin count that is rapidly rising (per clinical assessment) and at least 2 of the following manifestations as described in the ASTCT consensus criteria:
  • Onset with resolving/resolved CRS or worsening inflammatory response after initial improvement with CRS-directed therapy
  • Hepatic transaminase elevation§ (>5 × ULN (if baseline was normal) or >5 × baseline if baseline was abnormal)
  • Hypofibrinogenemia (\<150 mg/dL or \<LLN)
  • Hemophagocytosis in bone marrow or other tissue
  • Grade 1 cytopenias (new onset, worsening, or ) defined as:

    • Anemia () \<LLN* - 10.0 g/dL(gr1)
    • Neutropenia (ANC) 1,000 - 1,499/µL (Gr1)
    • Thrombocytopenia \<LLN - 75,000/µL (Gr1)
  • Lactate dehydrogenase elevations (>ULN)
  • Other coagulation abnormalities (e.g. elevated PT/)
  • Direct hyperbilirubinemia
  • New-onset splenomegaly that is palpable ≥5 cm below costal margin or >450cc on imaging
  • Fever of 100.4 or greater (new or persistent)
  • Neurologic changes greater than baseline that are consistent with a grade 1 Immune Effector Cell Encephalopathy (ICE) Score or greater
  • Pulmonary manifestations

    • Gr 2 Hypoxia with decreased oxygen saturation with exercise (e.g. pulse ox \<88%)
    • pulmonary infiltrates
    • pulmonary edema with radiologic findings and moderate dyspnea on exertion
  • New onset renal insufficiency defined by:

    • an absolute increase in serum creatinine of ≥0.3 mg/dL within 48 hours.
    • A baseline increase in serum creatinine of ≥1.5 times within the prior 7 days.
    • Oliguria defined as urine volume \<0.5 mL/kg/h for at least 6 hours.

      • Hypertriglyceridemia (fasting level, >265 mg/dL‖)
  • Patients who have received a CAR T product, commercially available or , will be allowed to enroll
  • (ECOG) Performance Score43 of 0-2
  • Patients may be treatment naïve for the IECH-HS diagnosis or may have received prior or ongoing treatment. can be continued along with RUX initiation as noted above.
  • Patient is able to take oral medication or is willing to have an NG tube placed if unable to take oral medication. Patients in whom NG tube was placed due to acute decompensation (resulting in an ECOG of >2), will be excluded.
  • Willing and able to sign an form

Exclusion criteria

Exclusion Criteria:

  • greater than 6 months
  • Patients with known active or known progressive underlying disease
  • Women who are pregnant or breastfeeding. Women must also refrain from breastfeeding during the course of study and for 60 days after the last dose of study treatment.
  • Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment. Participants with acute infection requiring antibiotic, antifungal, or antiviral treatment use should delay screening/enrollment until the course of antibiotic antifungal, or antiviral therapy has been completed and the infection is not active anymore.

Note: If a participant has a positive screening test result for SARS-CoV-2 infection, the participant should be excluded until test normalization and clinical recovery.

  • Any prior agent used to treat IEC-HS
  • Patient on treatment with rifampin, St Johns wart or other JAK inhibitors
  • Patient is unable to tolerate medicine administration either orally or via NG tube.
  • Known history of allergic reaction to ruxolitinib
  • History of or uncontrolled cardiac disease, including recent (within the last 12 months) unstable angina or acute myocardial infarction, or Class III or IV congestive heart failure, or clinically significant arrhythmias not controlled by medication. Participants with a pacemaker and well-controlled rhythm for at least 1 month before the first dose of study treatment will be allowed.
  • Any major surgery within 28 days before the first dose of study treatment.
  • Active (or at risk of reactivation), defined as follows: positive HBsAg result (laboratory test required at screening), and/or positive total anti-HBc result (laboratory test required at screening), and/or quantitative HBV DNA test result greater than the lower limits of detection of the assay (if known; laboratory test not required for eligibility purpose, but can be done as part of screening if available locally). Note: Participants with no prior history of HBV infection who have been vaccinated against HBV and who have a positive anti-HBs as the only evidence of prior exposure may participate in the study.
  • Active , defined as follows: positive anti-HCV result (laboratory test required at screening) and quantitative HCV RNA test result greater than the lower limits of detection of the assay (laboratory test only required if anti-HCV-positive, can be done as part of screening if available locally).

Note: Anti-HCV-positive participants who received and completed treatment for HCV that was intended to eradicate the virus may participate if HCV RNA levels are undetectable at least 12 weeks after the last dose of therapy. Anti-HCV-positive participants with no available confirmatory negative HCV RNA test results will be excluded.

  • Known history of (1/2 antibodies).
  • Any condition or circumstance that would, in the investigator's judgment, interfere with full participation in the study (eg, unable, unlikely, or unwilling to comply with the dose schedule and study evaluations, active alcohol or drug addiction), including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Ruxolitinib (RUX) therapy

    Patients will receive ruxolitinib at a dose of 5 mg twice a day if platelets are under 30,000/µL, ruxolitinib 10 mg twice a day if platelets are ≥30,000/µL but under 50,000/µL, or ruxolitinib 15 mg twice a day if platelets are ≥50,000/µL at the start of treatment. If a favorable response to ruxolitinib is noted (as defined in the protocol), patients will continue on treatment for at least 8 weeks if it is tolerated without significant side effects.

    Drug: Ruxolitinib

Interventions

  • In this study, Ruxolitinib will be supplied as 5 mg tablets which will be administered orally twice daily (BID) as an open-label, investigational product. Ruxolitinib dosing based on platelet numbers: * 5 mg twice a day if platelets are under 30,000/µL, * 10 mg twice a day if platelets are more than or equal to 30,000/µL but less than 50,000/µL, or * 15 mg twice a day if platelets are more than or equal to 50,000/µL Patients who respond may continue treatment for at least 8 weeks. Therapy will be discontinued for significant toxicity or evidence of IEC-HS progression. After 8 weeks, the dose may be tapered as clinically appropriate, with continued therapy permitted for up to 6 additional months if clinical benefit persists.

    Also known as: JAKAFI

06

What researchers measure

Primary outcomes

  1. Number of Participants with Clinical Response

    Determine clinical response at 8 weeks of RUX therapy. Clinical response (CLR) is defined as complete response, partial response or favorable response per below criteria in section 6.2 of the protocol.

    Time frame: 8 weeks

  2. Number of Adverse events

    Quantify number of Adverse events as monitored by CTCAE v6.0.

    Time frame: 8 weeks

Secondary outcomes

  1. Favorable response (FR) assessment

    Proportion of patients who are treated with ruxolitinib (RUX) for IEC-HS and who achieve at least a favorable response (FR) at week 1.

    Time frame: 1 week

  2. Complete response (CR) assessment

    Number of patients who achieve a complete response at 8 weeks

    Time frame: 8 weeks

  3. Median time to achieve FR

    Determine the median time for patients with IEC-HS to achieve at least FR with RUX.

    Time frame: 8 weeks

  4. Overall survival

    Overall survival at 3-months in patients who receive at least 1 dose of RUX for IEC-HS

    Time frame: 3 months

  5. Event-free survival

    Event free survival at 3-months in patients who receive at least 1 dose of RUX for IEC-HS. An "Event" includes addition of another therapeutic agent or change in treatment for IEC-HS, death, relapse of IEC-HS, and relapse of primary disease.

    Time frame: 3 months

  6. Participants With Improvement of cytopenias

    Proportion of patients whose grade 3-4 cytopenias improve to grade 2 or better on treatment with RUX.

    Time frame: 8 weeks

  7. Intensive care admission rate

    Proportion of patients who are admitted to intensive care (ICU for grade 3 or higher adverse events related to IEC-HS after initiation of RUX.

    Time frame: 8 weeks

  8. Participants With Development of infections, worsening cytopenias, and/or new transfusion dependence

    Proportion of patients who develop culture/assay-proven infections, worsening cytopenias, and/or new transfusion dependence upon treatment with RUX.

    Time frame: 8 weeks

  9. Overall response of disease

    Overall response of underlying disease at Day 90 post CAR T treatment in patients who develop IEC-HS.

    Time frame: 3 months

  10. Rate of relapse

    Rate of relapse of IEC-HS following discontinuation of RUX.

    Time frame: 6 months

  11. Time until start of new therapy of IEC-HS

    Determine the amount of time between completion of RUX and the start of additional therapy for IEC-HS if such is needed.

    Time frame: 6 months

Other outcomes

  1. Change in immunological biomarker response

    Evaluate changes in immunological biomarkers of inflammation (such as ferritin, fibrinogen, and triglycerides) and cytokine profiles known to be associated with IEC-HS.

    Time frame: 8 weeks

  2. CAR T cell expansion dynamics following RUX

    Evaluate dynamics of CAR T expansion following RUX treatment by monitoring CAR T-cell expansion and persistence patterns with RUX treatment by using fluorescence-activated cell sorting (FACS) to track CAR T-cell kinetics throughout treatment.

    Time frame: 8 weeks

  3. Optimal RUX treatment duration

    Determine the optimal duration of RUX therapy

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Jul 1, 2028
CompletionEst.
Feb 1, 2029
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07424222
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Jul 15, 2026
Primary completion
Jul 1, 2028 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Jul 28, 2026

Study contacts

Tania Jain, MBBS
Contact
tjain2@jhmi.edu
4109557035
Mary Amanda Stevens, MD
Contact
msteve35@jhmi.edu
Tania Jain, MBBS
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion